Outsourcing in Clinical Trials & Clinical Trial Supply Nordics 2022

Biography: Lene Grejs Petersen is Senior Adviser at the Danish Medicines Agency, Clinical Trial Unit. Lene is member of the Clinical Trials Coordinating and Facilitation Group (CTCG) member since 2008 and is the Danish representative of the EU Commission’s expert group concerning clinical trials (CTEG) since 2001. Lene has been an employee at the Danish Medicines Agency since 2000 and she has been involved in the implementation of the EU Clinical Trials Regulation into Danish legislation and works as a regulatory assessor and coordinator of clinical trials. Lene has a background as Master in Pharmacy.

Session Details: Highlights of the Clinical Trial Regulation experiences since 31 January 2022. Presented by the Danish Medicines Agency 25-10-2022, 8:30 am View In Agenda

Biography: Frederik Grell Nørgaard is Project Manager for decentralised trials at the Clinical Trial Unit, Danish Medicines Agency (DKMA). Frederik is working as a regulatory assessor and coordinator of clinical trials applications and runs several Danish initiatives such as the dialogue forum for decentralised trials (DCT). He is also the co-author and coordinator of the Danish DCT guidance. Frederik is a member of several workgroups within the Clinical Trials Facilitation and Coordination Group (CTFG) being involved in development of DCT guidance and a Q&A regarding the IVDR-CTR interface. Frederik has a background as Master in Pharmacy.

Session Details: View In Agenda

Biography: Helén Johansen Blanco has 20+ years of clinical development experience, managing Phase I to III clinical trials leading to the successful launch of several oncology products. She has experience in project management of large global clinical trials conducted in all continents of the world, mainly within oncology, but also therapeutic areas as cardiovascular and gastrointestinal. Mrs. Blanco has previously worked for large international pharma companies such as Astra Zeneca and Mylan, as well as small, medium to large sized biotechnology companies as Nordic Nanovector and Celgene, in addition to smaller and larger CROs such as Smerud and Covance. Currently she holds a position as Head of Clinical Operations at Oncoinvent, a small medium sized biotech company located in Norway. She holds a MSc in Biophysics and medical technology from Norwegian Technology and Science University and is currently writing her thesis for a Master in Business Administration.

Session Details: Chairperson’s Opening Remarks 25-10-2022, 8:15 am OUTSOURCING IN CLINICAL TRIALS 25-10-2022, Panel Discussion Solutions to fully adapt to the future of Decentralised Clinical Trials to ensure patient engagement and overall DCT success 25-10-2022, 11:00 am How to optimize collaboration with patient advocacy organizations 25-10-2022, 3:00 pm Chairperson’s closing remarks 25-10-2022, 5:30 pm Chairperson’s opening remarks 26-10-2022, 8:45 am OUTSOURCING IN CLINICAL TRIALS 26-10-2022, Chairperson’s closing remarks 26-10-2022, 5:00 pm View In Agenda

Biography:

Session Details: CLINICAL TRIAL SUPPLY 25-10-2022, The movement towards decentralized clinical trials 26-10-2022, 2:30 pm View In Agenda

Biography:

Session Details: Improving ways of working in the study design phase to reduce waste and cost of drugs 25-10-2022, 11:30 am View In Agenda

Biography: Morten Lind Jensen is VP of Medical Science at UNION Therapeutics A/S. Prior to working at UNION, Morten has 9 years of experience as medical specialist, project manager and line manager from Novo Nordisk, where he worked across the internal Novo Nordisk portfolio and established external collaboration projects within new ways of doing clinical trials and using digital data. Prior to joining the pharmaceutical industry, Morten did his Ph.D. within the research space of medical education, and on how to optimize learning outcomes during the training of professionals. He has also worked clinically as a medical doctor within radiology and surgery. Morten is an MD from University of Copenhagen, Denmark.

Session Details: Panel Discussion Solutions to fully adapt to the future of Decentralised Clinical Trials to ensure patient engagement and overall DCT success 25-10-2022, 11:00 am View In Agenda

Biography:

Session Details: Panel Discussion Solutions to fully adapt to the future of Decentralised Clinical Trials to ensure patient engagement and overall DCT success 25-10-2022, 11:00 am Decentralized clinical trials in ethical committees 25-10-2022, 2:00 pm View In Agenda

Biography: I am director of IND & Phase I (which includes clinical operation) in Symphogen/Servier (Symphogen was acquired by Servier in 2020) I have worked several years in a CRO and the industry as CRA, Senior CRA and PM before joining Symphogen in 2010, where I am now heading the IND & Phase I entity which includes clinical operation but also the responsibility of facilitating new compounds (mAb) when received a go to be explored in FIH to FPFV. Symphogen develops mAb within oncology.

Session Details: View In Agenda

Biography: Pernille Hemmingsen has more than a decade of experience in the development of pharmaceutical products. With a background in biophysical chemistry and chemical engineering, she is particularly interested in the development of robust manufacturing methods and solid quality to enable the best patient experience and convenience. This interest has led to the development of products ranging from cancer targeting liposomes and antibody drug conjugates to tamper resistant tablets and enhanced diabetes formulations at companies including Genmab and Novo Nordisk. Currently, Pernille Hemmingsen is responsible for the chemistry, manufacturing and control at Adcendo, taking to role as CTO. This work particularly includes establishing an efficient supply chain that encompasses elements from both biologics and small molecules. Pernille holds a Ph.D. from the Department of Chemistry at the Technical University of Denmark and an executive Master of Business Administration from Copenhagen Business School.

Session Details: FIRESIDE CHAT: Focusing on Technology & Innovation to ensure worldwide leadership in the field. 25-10-2022, 5:00 pm View In Agenda

Biography: Nigel Hughes has a thirty-six year career spanning the NHS in the UK (16 years), NGOs and patient organisations (10 years) and within the pharmaceutical industry (18 years). He has worked clinically in HIV and viral hepatitis, liver disease, and in sales & marketing, medical affairs, market access and health economics, R&D, precision medicine, advanced diagnostics, health IT and Real World Data/Real World Medicine. His experience covers clinical, education, as an advisor, consulting, communications and lobbying over the years. He is currently the Project Lead for the IMI2 European Health Data & Evidence Network (EHDEN), and was Platform Co-Lead for the IMI1 European Medical Information Framework (EMIF), as well as consulting on numerous projects and programmes in the domain of RWD/RWE.

Session Details: Real World Data and Real-World Evidence post COVID-19; responding to the systemic information dementia in healthcare 26-10-2022, 11:00 am View In Agenda

Biography:

Session Details: Medical Device Testing Panel Discussion: Best practices within medical device clinical trials in order to stay compliant 26-10-2022, 11:00 am Optimising your partnership strategy to turn your medical devices into reality 26-10-2022, 12:00 pm View In Agenda

Biography: Christian Friis – (Strategic Trial Planning Manager) brings more than 20 years of experience from the industry. Christian has worked in Regulatory, as CRA in a CRO and as International Trial Manager in Biotech for close to eight years. In 2010 Christian joined Ferring where he has had several roles with increasing responsibilities and latest he progressed into the role as Clinical Project Leader, in Global Clinical Operations. In 2021 Christian joined Global Trial Planning at Novo Nordisk and he is responsible for country allocation of the haemophilia trial portfolio.

Session Details: How to prepare for successful recruitment in Clinical Trials 26-10-2022, 4:30 pm View In Agenda

Biography: Ane H. Jensen (MA) Passionate about new technology and their ability to change the way we conduct clinical trials. Has worked at different positions in Novo Nordisk between 2008 and 2020. Since 2020 employed at Zealand Pharma. Previous experiences include RTSM, training, process improvements, logistics, clinical trials supplies and eLearning development.

Session Details: Great expectations and how to meet them – connected devices and ePRO in clinical trials 26-10-2022, 4:00 pm View In Agenda

Biography:

Session Details: Political challenges beyond our control: How pharma and biotech companies in the Nordic region can mitigate against this 25-10-2022, 11:00 am Panel Discussion Solutions to fully adapt to the future of Decentralised Clinical Trials to ensure patient engagement and overall DCT success 25-10-2022, 11:00 am Innovation & Creativity vs Reimbursement; Clinical trials as part of the innovation ecosystem – what elements affect our possibility to attract clinical trials 26-10-2022, 12:00 pm View In Agenda

Biography: Born in Moscow. Graduated in Russian State Medical University 1991-1997 followed by 3 years of Postgraduate specialisation in Neurology. MD degree in Neurology. Joined Pharmaceutical industry in 2000, having 7 years different regionals roles in Sales & Marketing. From 2007, relocation to Denmark, Nycomed HQs, different roles in R&D. From 2010 based in Switzerland, starting in Takeda, as CNS Franchise Head, then Head of Portfolio strategy and Business excellence. Executed 4 Global launches over the last 5 years in rare diseases, haemoonclology and CNS.

Session Details: Political challenges beyond our control: How pharma and biotech companies in the Nordic region can mitigate against this 25-10-2022, 11:00 am The Pursuit of Success: Driving your drug from the lab to the patient 25-10-2022, 4:00 pm View In Agenda

Biography:

Dr. John Zibert is Chief Medical Officer at LEO Innovation Lab, LEO Pharma’s independent innovation unit, where he leads a decentralized clinical trials unit, Studies&Me, working to personalize treatment development. Dr. Zibert has a history of more than seven year with LEO Pharma where he has held a number of positions as medical director for Region Europe, Medical advisor, Project leader and scientist. Dr. Zibert has senior experience with pharmaceutical drug development for various skin diseases, for which he contributed to the launch of two new products. He holds a B.Sc. in microbiology, M.Sc. in Human biology and a Ph.D. in medicine. 

John Zibert has been carrying out International clinical research on skin diseases and cancers for over a decade, with several publications in high-tier peer-reviewed journals. 

Prior to his scientific work, Dr. Zibert spent seven years in the Danish armed forces’ health and sports sector, and as a paramedic.

Session Details: View In Agenda

Biography: Having had a normal weight in childhood, obesity entered my life when I had my child in 1993. I gained a total of 40 kg over the next 14 years despite diet monitoring, physical exercise and obesity medication available back in time. No matter what I did I couldn’t stop putting on weight… I was almost 100 kg in 2007 and the consequences of so much weight were so clear: pain in lower back, ankles and knees, fat in my liver but even more scary – high blood sugar levels. I was a single mother and my only concern was that my health would deteriorate so badly that I’d leave my kid an orphan. As nothing less invasive seemed to help me in losing my body weight, I decided to have bariatric surgery. Although I’m having a normal weight for the last 11 years, I still struggle every day to keep it in control. Today I use my story to advocate for the cause of defeating Obesity together with my scientific background. I am a pharmacist contributing that better and effective drug treatment for losing weight is available to an affordable cost to all people in need of it. The collaborative relationship between patients living with a chronic disease and pharma is a win-win situation. Patient experiences, perception and opinions are heard by the companies behind new therapeutic options that hopefully will bring more quality to patients' life. This close dialogue helps to educate and raise the awareness of the burden caused by these diseases both on an individual and society perspective. The potential products can show exciting results in the laboratory and animals but only patients have the actual experience in their disease control. By giving the patients the opportunity of sharing their feedback from beginning of a product development the companies are able to make available better treatment options that meet patients' expectations on a faster fashion.

Session Details: The Patient's Perspective: ‘Why are patient's voices so important in clinical development?’ 25-10-2022, 9:30 am View In Agenda

Biography: Dr Christine Natasha Ryan holds a PhD in Neuroscience from the University of Cambridge, Cambridge, UK and an MBA from Stockholm School of Economics. Following a post-doc at the Brain Research Institute, St. Hans Hospital, Roskilde, Denmark, Dr Ryan remained in Scandinavia moving to Sweden to work at Astra, which then became AstraZeneca, holding line management and competitive intelligence roles. Dr Ryan has engaged in preclinical research at blue chip companies such as AstraZeneca, smaller pharmaceutical companies, CROs and biotechs, working at Karo Bio AB, and Cerca Insights among others. Dr Ryan joined Gabather AB as Principal Scientist in 2017, becoming VP Operations in 2018. She is currently COO.

Session Details: Political challenges beyond our control: How pharma and biotech companies in the Nordic region can mitigate against this 25-10-2022, 11:00 am Lessons Learnt from Phase I Clinical Trials: Real World Experience 25-10-2022, 5:00 pm View In Agenda

Biography:

Session Details: Case Study: Considerations on sponsor oversight of vendor computerized systems applied in clinical trials From a Clinical Operations point of view - experiences post a European Authority GCP inspection looking into: 26-10-2022, 1:30 pm View In Agenda

Biography:

Session Details: Medical Device Testing Panel Discussion: Best practices within medical device clinical trials in order to stay compliant 26-10-2022, 11:00 am EU Medical Device Regulation: Classification as a Key to Regulatory Strategy 26-10-2022, 1:30 pm View In Agenda

Biography: I have more than 20 years of experience in sales and marketing from Life Science. In recent years, my focus has been on Medical Devices - both B2B and B2C. I am responsible for strategy, commercialization and execution. I have extensive knowledge of Regional and Municipal decision-making processes, including EU tenders. My strength is the understanding from the interaction between customers, products, government agencies and suppliers.

Session Details: Defining Medical Device practice to push your product to market; based on real-life product launches, I will highlight how we push a Medical Device to market. 26-10-2022, 2:00 pm View In Agenda

Biography: Niklas Lindberg specializes in business development in the biotech industry. Niklas has over 30 years of experience in international business development and has worked in several countries and with focus on knowledge driven decision making and development plans. Niklas has experience from clinical development in Biotech, MedTech and big pharma developing their R&D pipelines and strategies. Niklas joined Novotech 2022.

Session Details: View In Agenda

Biography: Claudia Hesselmann, a chemist by training, with a PhD in molecular biology. Claudia has twenty years of expertise in the early phases of drug development. Her experience includes co-founding and holding management positions in various CROs. Her extensive background and social acumen, along with her first-hand knowledge of the industry, led Claudia to co-found ARENSIA Exploratory Medicine in Düsseldorf, Germany. Her primary aim is the contribution of innovative approaches to bring about substantial acceleration to the drug development process and enable more agile patient access to novel therapeutics.

Session Details: Accelerated performance of complex exploratory patient studies: practical insights from investigational site 25-10-2022, 4:30 pm View In Agenda

Biography: A UK top 100 influential tech leader passionate about diversity and inclusion practices. Innovation award winning pharma industry advisory consultant, founder, disruptor, passionate operational strategy expert, blockchain advocate, technology enabled clinical trials and patient engagement thought leader with over 20 years in the NHS on commission by the DOH and in Industry (Hoffman La-Roche, Amgen, ALMAC, ICON, Biogen and Novartis). As a part of R&D transformation led the strategy and implemented hybrid decentralized trials into the clinical development operating model at Biogen. Part of DIA Patient Engagement Voluntary Community Leadership team. Driver for change through identifying unmet customer needs, digital strategies, implementation and expansion of disruptive digital platform technologies across drug development and commercial lifecycles. Experience across various therapeutic areas and phases of trials in drug development including leading all phases of global clinical trials, developing electrophysiological clinical endpoints, creation and execution of successful strategies for research protocols and CRO oversight, patient and site feasibility, expertise in technologies such as eCOA, eConsent, telemedicine and IRT, creation of optimal drug packaging and administration concepts, mapping the patient journey, planning and executing effective global site and patient engagement campaigns using direct to patient methods, leading and coaching remote and complex global teams. Awards: • Financial Times 2019 Top 100 UK influential BAME tech leader • Founder of award winning Not-for-Profit to advance Clinical Trials in Emerging Markets in 2018 • Women Innovation Network UK Co-Lead (2016 Honorary Mention for Diversity and Inclusion Award) • Sunday Times UK ‘Rising Stars in Healthcare’ award in 2018 • Innovation award winner on clinical endpoints in 2014 • Nigerian diplomats wives award for donation of medical supplies in 2003 Notable Achievements include: • BBC Radio interview in 2020 on STEM activities and careers • Implemented lay language summary and end of study patient surveys • MBA dissertation titled ‘Implementing Patient Engagement at a Biotechnology Company’ • Conducted management consulting visit in Chile and various global consulting assignments • Keynote speaker and chair at various international conferences • Setting up mentoring programs and leadership workshops • Trustee for a youth charity in London

Session Details: Diversity in Finding New Medicines 25-10-2022, 12:00 pm View In Agenda

Biography:

Session Details: Medical Device Testing Panel Discussion: Best practices within medical device clinical trials in order to stay compliant 26-10-2022, 11:00 am View In Agenda

Biography: As Head of Special Cargo at the International Air Transport Association (IATA), Dr Sonia Ben Hamida leads the development of the special cargo agenda, delivering standards, business processes, and solutions for the air cargo supply chain related to the transport of live animals, perishables, and temperature-sensitive cargo, and all other special cargo.   Prior to joining IATA, Sonia held several roles in France where she spent 8 years driving innovation in the aerospace industry. Then she joined academia in 2019 as a lecturer and researcher at EPFL, the Swiss Federal Institute of Technology in Lausanne, and UNIGE, the University of Geneva. Over the past 12 years, I have built a strong expertise in project management, innovation, design, and business and systems modeling.   Sonia holds an engineering degree in Aviation and Computer Science from the French Civil Aviation University - ENAC (France) and a PhD in Innovation from CentraleSupélec (France).

Session Details: Temperature Controlled Airfreight Global Logistics for Clinical Trials 25-10-2022, 2:00 pm Supply Chain Panel: Ensuring the highest level of collaboration between clinical trial supply and clinical operations 25-10-2022, 3:00 pm View In Agenda

Biography: Heading up a change management office at Novo Nordisk to support digitalization, decentralized trials and new ways of working across the clinical drug development landscape. Has over 15 years of experience driving change across companies like AP Moller Maersk, Grundfos, GN Store Nord and Leo Pharma including supply chain and HR transformations, M&A, ERP deployment and organizational redesign.  

Session Details: Supply Chain Panel: Ensuring the highest level of collaboration between clinical trial supply and clinical operations 25-10-2022, 3:00 pm View In Agenda

Biography: Sverre Bengtsson started in the clinical trials industry over 30 years ago. He started as a statistician/statistical programmer, later into data management and since over 20 years into business development. He has been working in both CRO’s as well as in clinical trials technology companies, including the global first ePRO company. Sverre is very interested in making clinical trials efficient, in both study design but also in the processes and technologies used.   Sverre co-founded Viedoc Technologies 19 years ago and is responsible for some of the major accounts but also the vision around the company. He’s on the board of both some industry organisations and in clinical technology companies.

Session Details: Decentralized clinical trials and hybrid trials: what you need to understand to run these successfully 25-10-2022, 10:00 am View In Agenda

Biography: Kevin has 4 years of experience in industry, research and medical environments. In these fields he has been developing innovative projects in medical software technology and AI. He is a Biomedical Engineer by training and holds an MSc in Artificial Intelligence from Essex University in the UK. He is committed to contributing to the development of gold-standard techniques for real-world data collection from sensors, digital biomarker discovery, preventive medicine and AI applications in healthcare.

Session Details: Developing a More Complete Picture of the Patient Experience Through an Integrated Approach to eCOA and Sensors 25-10-2022, 9:00 am Panel Discussion Solutions to fully adapt to the future of Decentralised Clinical Trials to ensure patient engagement and overall DCT success 25-10-2022, 11:00 am View In Agenda

Biography: Derek Ansel is Executive Director, Therapeutic Strategy Lead, Rare Disease at Worldwide Clinical Trials.  Mr. Ansel has worked in clinical research for more than a decade with a focus almost exclusively in rare and pediatric diseases, including non-malignant hematology, autoimmune diseases, metabolic disorders, movement disorders, and other genetic conditions. At Worldwide, he leads and supports corporate initiatives within rare and pediatric diseases and maintains relationships with over 60 patient-focused advocacy organizations. He holds a master’s degree in Pharmacology and Toxicology from Michigan State University and is pursuing a master’s degree in Genetic Counseling from Bay Path University.

Session Details: Next evolution of operational considerations in rare disease trials 25-10-2022, 11:30 am View In Agenda

Biography: Antoine Remiot has been sharing his enthusiasm and technical advice to various pharma partners, helping them tackle clinical trial supply challenges and solve drug shortage. He truly enjoys complex situations where he can use his skills to solve tricky problems. Antoine has a Master’s Degree in Mechanical Engineering with a focus on optimization. After working for various optimization software companies in the aeronautical market, he joined N-SIDE to focus on new pharma companies

Session Details: Improving ways of working in the study design phase to reduce waste and cost of drugs 25-10-2022, 11:30 am View In Agenda

Biography: Achilleas has 12+ years of experience in software industry involving software demonstrations, managing a team of 15+ developers, hands-on coding in Microsoft .Net platform and Business Intelligence Suites like QlikSense. He has enjoyed a progressive career in diverse roles including responsibilities of a Sales Engineer, Team Manager, Software Engineer and Business Intelligence Analyst in various industries like Banking, Retail and now the Pharmaceutical industry with eClinical Solutions.

Session Details: Data-Driven Operations and Oversight with elluminate 25-10-2022, 12:30 pm View In Agenda

Biography: Dr Florence Mowlem is Medable’s Subject Matter Expert on digitising the capture of Clinical Outcome Assessments (COAs) in clinical trials, ensuring optimal solutions for clients that meet the scientific needs of their studies. She contributes expertise on solution design for all eCOA types (ePROs, eClinROs, eObsROs, ePerfOs, eDiaries) and advises around project complexities, to ensure adherence with the protocol requirements, that industry best practices are followed, and regulatory considerations accounted for. Flo is an active member of industry consortium (C-PATH eCOA, DIA), has presented at international conferences, and has numerous peer-reviewed publications. Flo has an MSc and PhD in Social, Genetic, & Developmental Psychiatry from the Institute of Psychiatry, Psychology, & Neuroscience (King’s College London), where her research focused on sex differences in the diagnosis and treatment of Attention Deficit Hyperactivity Disorder (ADHD), and the psychometric evaluation and validation of a new patient-reported measure for use in adult ADHD.

Session Details: Employing Flexibility in Oncology Clinical Trial Designs to Facilitate Patient-Focused Drug Development 25-10-2022, 2:30 pm View In Agenda

Biography: Niklas Lindberg specializes in business development in the biotech industry. Niklas has over 30 years of experience in international business development and has worked in several countries and with focus on knowledge driven decision making and development plans. Niklas has experience from clinical development in Biotech, MedTech and big pharma developing their R&D pipelines and strategies. Niklas joined Novotech 2022.

Session Details: View In Agenda

Biography: Libbi Rickenbacher, Director of Strategy, has over 15 years of experience in the field of life sciences, and is an e-clinical RTSM solutions subject matter expert. Her experience lies at building and managing accounts, clients, and strategic initiatives. Has a proven record of success in conceptualizing and delivering client focused solutions, standards, and providing oversight and guidance to both internal and external teams. Holds BA in both Neuroscience and Psychology and a Doctorate (PhD) in Neuroscience

Session Details: Navigating Complexity Through the Lens of the End-User 25-10-2022, 12:30 pm View In Agenda

Biography: Heike is the Shareholder and Co-Founder of Lumis International, Lumis Life Science Consulting and the newly founded UK branch Lumis International Limited. She has more than 25 years of experience in leadership positions in international clinical research and drug development. She has profound knowledge of the clinical drug development processes and regulatory requirements from first in human to market access. She is experienced in developing strategies and concepts for biopharmaceutical and medical device companies covering clinical operations, clinical research, outsourcing, vendor management and oversight management.

Session Details: View In Agenda

Biography: Alexis Davin is a clinical optimization specialist at N-SIDE and a volunteer at the GCSG. His experience in clinical supply expanded quickly by solving day-to-day supply challenges of biopharma companies. He is passionate about how digitalization can improve the clinical supply industry and, ultimately, impact patients’ health. Alexis is also supporting the development of new digital solutions to solve supply chain issues in clinical trials, which offers him a strategic view on industry trends and internal processes.

Session Details: View In Agenda

Biography: Jan Talts has extensive R&D and management experience from academia, the biotech industry, and the health care sector. He earned his PhD in Animal Physiology at Uppsala University working with extracellular matrix molecules in development and disease and has since then held positions as Associate Professor at Lund University Medical Faculty, Associate Professor and Section Leader for Anatomy and Cell Biology at the Royal Veterinary and Agricultural University, Copenhagen, Chief Medical Staff, Clinical Pathology, Lund University Hospital, and Senior Scientist, Project Manager and ECA certified QA Manager at the Swedish Regenerative Medicine Company Xintela AB. During the last years, he has been with Amniotics AB, first as Senior Scientist, then Chief Quality Officer and now Chief Operating Officer. He is the inventor on several patents and has published articles in international journals such as Cell, Molecular Cell, EMBO J, and PNAS. Jan Talts is well familiarized with most aspects of Advanced Therapy Medicinal Product (ATMP) development and have hands on experience within the preclinical, CMC, and regulatory fields.

Session Details: View In Agenda

Biography: Daniela Duffett is the European Solutions Consultant at Suvoda, based out of our Barcelona office. She consults with clients and prospects, delivering presentations and demonstrations, while acting as a Subject Matter Expert on Suvoda’s solutions. She started at Suvoda three years ago on the Project Management side of our Services Delivery organisation, so can impart her hands-on delivery experience & knowledge.  

Session Details: Making Clinical Supply More Effective: IRT as a tool to Manage Your Trial Supply Chain with Flexibility, Visibility and Control 25-10-2022, 4:30 pm View In Agenda

Biography: I am an international business lawyer with an important corporate and transactional practice within the LifeSciences industry, mainly dealing with clinical R&D, finance, manufacture and logistics. I am from Spain but trained and with practice in the US, Latin America and, more recently, in the Nordics. I developed a deep expertise on: (i) Trading, infrastructure, public bidding processes; (ii) M&A, patent licensing, tax strategies; (iii) Foreign trade, customs, international business practices; (iv) Intellectual Property, IP monetization, technology transfer; and (v) implementation of strategies for small biotechs to become global. Currently I am the Head of Legal Affairs & Compliance at Pila Pharma AB in Sweden.

Session Details: Building CRO Relationships. What are the critical factors to consider when procuring from a CRO? 26-10-2022, 3:30 pm View In Agenda

Biography: Arrash is an academic paediatrician at Imperial College, and is Huma's Global Clinical Director. His previous national roles included working at the Department of Health and NHS England/Improvement. His healthcare experience includes some of the largest healthcare projects to date, including the 7-day hospital services programme and a range of other national initiatives.

Session Details: Case study: Patient engagement and adherence in Decentralised clinical trials; an introduction to the DTaP study completed by Huma, Bayer, and Stanford University 26-10-2022, 2:00 pm View In Agenda

Biography: A trained  scientist with more than 15 years of international experience and expertise working in the pharmaceutical and biotech industries, Dennis joined Huma earlier in 2022 with the mission to build and lead the Decentralised Clinical Trials’ (DCT) team in EMEA. Working on a daily basis with Sponsors and CROs, helping them build efficient ecosystems for their clinical trials, assessing the implementation of a decentralized  / hybrid trials’ strategy is what drives Dennis. It is about making a significant  impact on research and access to research and cures. Prior to Huma, Dennis was at Medable, ERT, BioClinica, Oracle, and he started his career at Thomson Reuters. A native from Colombia, Dennis is a professional scuba rescue driver who can be found training at the gym and walking / cycling to the office on a daily basis. “I am passionate about delivering everything I am involved in to the highest standards. I believe it is paramount to fulfil my promises all the time and in the best possible way.’

Session Details: Case study: Patient engagement and adherence in Decentralised clinical trials; an introduction to the DTaP study completed by Huma, Bayer, and Stanford University 26-10-2022, 2:00 pm View In Agenda

Biography:

Session Details: View In Agenda

Biography:

Session Details: From Molecule to Market 25-10-2022, 2:30 pm View In Agenda